Mirati Therapeutics Inc.’s (MRTX) Adagrasib, an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C mutation, is under FDA review, with a decision due on December 14, 2022.Adagrasib, proposed for the treatment of patients with non-small cell lung cancer harboring the KRASG12C mutation who have received at least one prior systemic therapy, is being reviewed for Accelerated Approval, based on a surrogate endpoint.If approved, Adagrasib will have to compete with Amgen’s Lumakras, the first KRAS targeted therapy to secure approval last May.For the third quarter ended Sept. 30, 2022, Lumakras generated revenue of $75 million, up from $36 million in the year-ago period.Under an agreement signed in June 2021, Zai Lab Ltd. (ZLAB) obtained the right to develop and exclusively commercialize Adagrasib in mainland China, Hong Kong, Macau and Taiwan.MRTX closed Friday’s trading at $98.62, up 2.89%.